

INVITE TO INVESTOR WEBINAR ON SYMPHONY RCT

Aroa Biosurgery Limited (ASX: ARX, 'AROA' or the 'Company') will host an investor webinar on Monday 12 October 2026 to discuss the recently published findings from the Symphony Randomised Controlled Trial.

Hosted by AROA Founder and CEO Brian Ward, the webinar will feature Chief Scientific Officer Dr Barnaby May and Dr Brandon Bosque discussing the findings and their clinical significance. Brian will discuss the commercial implications for AROA.

Investors and other interested parties can register for the webinar here:

https://us02web.zoom.us/webinar/register/WN_XfcdCOMxQpeHf3G-z8_lzg

Questions may be submitted during the webinar using the online Q&A function.

<ENDS>

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

Contact

investor@aroa.com

About AROA™
Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix bioscaffold derived from ovine (sheep) forestomach. Over 7 million AROA devices have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELABio, Inc. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroa.com